Addus HomeCare (ADUS) Stock Forecast & Price Target

Addus HomeCare is supported by a resilient core Personal Care franchise that delivered 6.5% same-store revenue growth in 1Q26, 5.2% higher billable hours, and a 12.2% adjusted EBITDA margin, showing solid operating leverage despite modest revenue misses. Its outlook is further strengthened by a favorable regulatory backdrop and improving rate dynamics in key markets such as Illinois and Indiana, where management is expanding through acquisitions like HomeCourt Home Care and a second planned franchise. With $103M in cash, $94M in debt, and expected 2026 EBITDA and free cash flow of $196M and $120M, respectively, the company appears well positioned to pursue larger M&A and compound growth.

Addus HomeCare is exposed to significant policy and reimbursement risk because more than 20% of revenue comes from the Illinois CCP, while the finalized May 2024 Medicaid Access Rule, minimum-wage-driven rate pressure, and possible cuts to Medicare hospice and home health reimbursement could compress margins, especially in states where service margins exceed 20%. Operationally, the 1Q26 results showed only modest upside versus estimates, with $363.6M of revenue and $44.5M of EBITDA, while hospice revenue missed expectations at $66M and home health revenue of $16.7M fell on a 15% Y/Y decline in visits, suggesting uneven execution across segments. Even with 8.1% Y/Y hospice census growth and 31.9% gross margin, the combination of weather disruption, labor constraints, and potential Gentiva integration issues leaves the company vulnerable to slower growth and margin pressure.